Substituted azole derivatives as therapeutic agents

• US 20040192743A1
• Filed: 02/12/2004
• Published: 09/30/2004
• Est. Priority Date: 02/12/2003
• Status: Abandoned Application

• Current Assignee: Transtech Pharma Incorporated
• Original Assignee: Transtech Pharma Incorporated
• Inventors: Subramanian, Govindan, Andrews, Robert C., Mjalli, Adnan M.M., Arimilli, Murty N., Xie, Rongyuan, Polisetti, Dharma R., Yarragunta, Ravindra R., Quada, James C. Jr.
• Application Number:
  US10/777,488
• Publication Number:
  US 20040192743A1
• Time in Patent Office: Days
• US Class Current: 514/365
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/02 of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
• CPC Class Codes: C07D 233/54 having two double bonds between ring members or between ring members and non-ring members
• CPC Class Codes: C07D 263/32 with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• CPC Class Codes: C07D 401/10 linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 403/10 linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 405/10 : linked by a carbon chain containing aromatic rings
• CPC Class Codes: C07D 405/12 : linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 413/04 : directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 417/12 : linked by a chain containing hetero atoms as chain links

Abstract

This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.

Claims

1. A compound of Formula (I):

2. The compound according to claim 1, wherein W is —

O—

or —

N(R₂)—

, wherein R₂ is hydrogen, alkyl, or —

L₃—

D-alkylene-aryl, wherein L₃ is alkylene, and D is —

CO(NR₅)—

, wherein R₅ is hydrogen.

3. The compound according to claim 1, wherein R₁ is hydrogen or aryl.

4. The compound according to claim 1, wherein R₁ is hydrogen.

5. The compound according to claim 1, wherein L₁ is

6. The compound according to claim 1, wherein L₁ is

7. The compound according to claim 1, wherein Ar₁ is a phenyl or naphthyl group optionally having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) -cyano;

f) -nitro;

g) -perfluoroalkyl;

h) —

J—

R₁₄;

i) -alkyl;

j) -aryl;

k) -heteroaryl;

l) -heterocyclyl;

m) -cycloalkyl;

n) —

L₅-aryl;

o) —

L₅-arylene-aryl;

p) —

L₅-arylene-alkyl;

q) -arylene-alkyl;

r) -arylene-arylene-alkyl;

s) —

J-alkyl;

t) —

J-aryl;

u) —

J-alkylene-aryl;

v) —

J-arylene-alkyl;

w) —

J-alkylene-arylene-aryl;

x) —

J-arylene-arylene-aryl;

y) —

J-alkylene-arylene-alkyl;

z) —

L₅—

J-alkylene-aryl;

aa) -arylene-J-alkyl;

bb) —

L₅—

J-aryl;

cc) —

L₅—

J-heteroaryl;

dd) —

L₅—

J-cycloalkyl;

ee) —

L₅—

J-heterocyclyl;

ff) —

L₅—

J-arylene-alkyl;

gg) —

L₅—

J-alkylene-arylene-alkyl;

hh) —

L₅—

J-alkyl;

ii) —

L₅—

J—

R₁₄;

jj) -arylene-J—

R₁₄; and

ll) -hydrogen;

 

wherein

L₅ is a direct bond, -alkylene, -alkenylene, or -alkynylene;

J is a direct bond, —

CH₂—

, —

O—

, —

N(R₁₅)—

, —

C(O)—

, —

CON(R₁₅)—

, —

N(R₁₅)C(O)—

, —

N(R₁₅)CON(R₁₆)—

, —

N(R₁₅)C(O)O—

, —

OC(O)N(R₁₅)—

, —

N(R₁₅)SO₂—

, —

SO₂N(R₁₅)—

, —

C(O)—

O—

, —

O—

C(O)—

, —

S—

, —

S(O)—

, —

S(O₂)—

, —

N(R₁₅)SO₂N(R₁₆)—

, —

N═

N—

, or —

N(R₁₅)—

N(R₁₆)—

,

 

wherein

R₁₄, R₁₅, and R₁₆ are independently selected from a group consisting of;

-hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl.

8. The compound according to claim 1, wherein Ar₁ is a phenyl group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) -cyano;

f) -nitro; and

g) -aryl.

9. The compound according to claim 1, wherein Ar₁ is a phenyl group substituted 1 to 5 times, wherein the substituents are selected from the group consisting of:

-chloro or -fluoro.

10. The compound according to claim 1, wherein Ar₂ is a phenylene or naphthylene group optionally having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) -cyano;

f) -nitro;

g) -perfluoroalkyl;

h) —

Q—

R₁₇;

i) -alkyl;

j) -aryl;

k) -heteroaryl;

l) -heterocyclyl;

m) -cycloalkyl;

n) —

L₆-aryl;

o) —

L₆-arylene-aryl;

p) —

L₆-arylene-alkyl;

q) -arylene-alkyl;

r) -arylene-arylene-alkyl;

s) —

Q-alkyl;

t) —

Q-aryl;

u) —

Q-alkylene-aryl;

v) —

Q-arylene-alkyl;

w) —

Q-alkylene-arylene-aryl;

x) —

Q-arylene-arylene-aryl;

y) —

Q-alkylene-arylene-alkyl;

z) —

L₆—

Q-alkylene-aryl;

aa) -arylene-Q-alkyl;

bb) —

L₆—

Q-aryl;

cc) —

L₆—

Q-heteroaryl;

dd) —

L₆—

Q-cycloalkyl;

ee) —

L₆—

Q-heterocyclyl;

ff) —

L₆—

Q-arylene-alkyl;

gg) —

L₆—

Q-alkylene-arylene-alkyl;

hh) —

L₆—

Q-alkyl;

ii) —

L₆—

Q-alkylene-aryl-R₁₇;

jj) —

L₆—

Q-alkylene-heteroaryl-R₁₇;

kk) -arylene-Q-alkylene-R₁₇;

ll) -heteroarylene-Q-alkylene-R₁₇;

mm) —

L₆—

Q-aryl-R₁₇;

nn) —

L₆—

Q-heteroarylene-R₁₇;

oo) —

L₆—

Q-heteroaryl-R₁₇;

pp) —

L₆—

Q-cycloalkyl-R₁₇;

qq) —

L₆—

Q-heterocyclyl-R₁₇;

rr) —

L₆—

Q-arylene-alkyl-R₁₇;

ss) —

L₆—

Q-heteroarylene-alkyl-R₁₇;

tt) —

L₆—

Q-alkylene-arylene-alkyl-R₁₇;

uu) —

L₆—

Q-alkylene-heteroarylene-alkyl-R₁₇;

vv) —

L₆—

Q-alkylene-cycloalkylene-alkyl-R₁₇;

ww) —

L₆—

Q-alkylene-heterocyclylene-alkyl-R₁₇;

xx) —

L₆—

Q-alkyl-R₁₇;

yy) —

L₆—

Q—

R₁₇;

zz) -arylene-Q—

R₁₇;

aaa) -heteroarylene-Q—

R₁₇;

bbb) -heterocyclylene-Q—

R₁₇;

ccc) —

Q-alkylene-R₁₇;

ddd) —

Q-arylene-R₁₇;

eee) —

Q-heteroarylene-R₁₇;

fff) —

Q-alkylene-arylene-R₁₇;

ggg) —

Q-alkylene-heteroarylene-R₁₇;

hhh) —

Q-heteroarylene-alkylene-R₁₇;

iii) —

Q-arylene-alkylene-R₁₇;

jjj) —

Q-cycloalkylene-alkylene-R₁₇;

kkk) —

Q-heterocyclylene-alkylene-R₁₇

lll) —

Q-alkylene-arylene-alkyl-R₁₇;

mmm) —

Q-alkylene-heteroarylene-alkyl-R₁₇;

ppp) -hydrogen

 

wherein

L₆ is a direct bond, -alkylene, -alkenylene, or -alkynylene;

Q is a direct bond, —

CH₂—

, —

O—

, —

N(R₁₈)—

, —

C(O)—

, —

CON(R₁₈)—

, —

N(R₁₈)C(O)—

, —

N(R₁₈)CON(R₁₉)—

, —

N(R₁₈)C(O)O—

, —

OC(O)N(R₁₈)—

, —

N(R₁₈)SO₂—

, —

SO₂N(R₁₈)—

, —

C(O)—

O—

, —

O—

C(O)—

, —

S—

, —

S(O)—

, —

S(O₂)—

, —

N(R₁₈)SO₂N(R₁₉)—

, —

N═

N—

, or —

N(R₁₈)—

N(R₁₉)—

;

 

wherein

R₁₈ and R₁₉ are independently selected from the group consisting of;

-hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl;

V is

Z is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R₁₇ is —

SO₃H, —

P(O)(OH)₂, —

P(O)(O-alkyl)(OH), —

CO₂H, —

CO₂-alkyl, an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

11. The compound according to claim 1, wherein Ar₂ is a phenyl group or naphthyl group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) —

Q—

R₁₇;

f) -alkyl;

g) -aryl;

h) -arylene-alkyl;

i) —

Q-alkyl; and

j) -arylene-Q-alkyl;

 

wherein

Q is —

CH₂—

, —

O—

, —

C(O)—

, or —

C(O)—

O—

, and

R₁₇ is;

-hydrogen, -alkyl, -aryl, —

CO₂H, or an acid isostere.

12. The compound according to claim 1, wherein Ar₂ is a phenyl group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) —

Q—

R₁₇;

f) -alkyl;

g) -phenyl;

h) -phenylene-alkyl;

i) —

Q-alkyl; and

j) -phenylene-Q-alkyl;

 

wherein

Q is —

CH₂—

, —

O—

, —

C(O)—

, —

C(O)—

O—

, and

R₁₇ is;

-hydrogen, -alkyl, -phenyl, or —

CO₂H.

13. The compound according to claim 1, wherein L₂ is:

—

CH₂—

, —

O—

, alkylene, alkenylene, —

O-alkylene-, -alkylene-O—

, —

N(R₂₀)—

, —

C(O)—

, —

CON(R₂₀)—

, —

N(R₂₀)C(O)—

, —

N(R₂₀)CON(R₂₁)—

, —

N(R₂₀)C(O)O—

, —

OC(O)N(R₂₀)—

, —

N(R₂₀)SO₂—

, —

SO₂N(R₂₀)—

, —

C(O)—

O—

, —

O—

C(O)—

, —

S—

, —

S(O)—

, —

S(O₂)—

, —

N(R₂₀)SO₂N(R₂₁)—

, —

N═

N—

, or —

N(R₂₀)—

N(R₂₁)—

or a direct bond, wherein R₂₀ and R₂₁ independently selected from the group consisting of;

-hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl.

14. The compound according to claim 1, wherein L₂ is:

—

O—

, —

O-alkylene-, -alkylene-O, or a direct bond.

15. The compound according to claim 1, wherein L₂ is:

—

O-alkylene- or a direct bond.

16. The compound according to claim 1, wherein T is an aryl group optionally having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) -cyano;

f) -nitro;

g) -perfluoroalkyl;

h) —

U—

R₂₂;

i) -alkyl;

j) -aryl;

k) -heteroaryl;

l) -heterocyclyl;

m) -cycloalkyl;

n) —

L₇-aryl;

o) —

L₇-arylene-aryl;

p) —

L₇-arylene-alkyl;

q) -arylene-alkyl;

r) -arylene-arylene-alkyl;

s) —

U-alkyl;

t) —

U-aryl;

u) —

U-alkylene-aryl;

v) —

U-arylene-alkyl;

w) —

U-alkylene-arylene-aryl;

x) —

U-arylene-arylene-aryl;

y) —

U-alkylene-arylene-alkyl;

z) —

L₇—

U-alkylene-aryl;

aa) -arylene-U-alkyl;

bb) —

L₇—

U-aryl;

cc) —

L₇—

U-heteroaryl;

dd) —

L₇—

U-cycloalkyl;

ee) —

L₇—

U-heterocyclyl;

ff) —

L₇—

U-arylene-alkyl;

gg) —

L₇—

U-alkylene-arylene-alkyl;

hh) —

L₇—

U-alkyl;

ii) —

L₇—

U-alkylene-aryl-R₂₂;

jj) —

L₇—

U-alkylene-heteroaryl-R₂₂;

kk) -arylene-U-alkylene-R₂₂;

ll) -heteroarylene-U-alkylene-R₂₂;

mm) —

L₇—

U-aryl-R₂₂;

nn) —

L₇—

U-heteroarylene-R₂₂;

oo) —

L₇—

U-heteroaryl-R₂₂;

pp) —

L₇—

U-cycloalkyl-R₂₂;

qq) —

L₇—

U-heterocyclyl-R₂₂;

rr) —

L₇—

U-arylene-alkyl-R₂₂;

ss) —

L₇—

U-heteroarylene-alkyl-R₂₂;

tt) —

L₇—

U-alkylene-arylene-alkyl-R₂₂;

uu) —

L₇—

U-alkylene-heteroarylene-alkyl-R₂₂;

vv) —

L₇—

Q-alkylene-cycloalkylene-alkyl-R₂₂;

ww) —

L₇—

Q-alkylene-heterocyclylene-alkyl-R₂₂;

xx) —

L₇—

U-alkyl-R₂₂;

yy) —

L₇—

U—

R₂₂;

zz) -arylene-U—

R₂₂;

aaa) -heteroarylene-U—

R₂₂;

bbb) -heterocyclylene-U—

R₂₂;

ccc) —

U-alkylene-R₂₂;

ddd) —

U-arylene-R₂₂;

eee) —

U-heteroarylene-R₂₂;

fff) —

U-alkylene-arylene-R₂₂;

ggg) —

U-alkylene-heteroarylene-R₂₂;

hhh) —

U-heteroarylene-alkylene-R₂₂;

iii) —

U-arylene-alkylene-R₂₂;

jjj) —

U-cycloalkylene-alkylene-R₂₂;

kkk) —

U-heterocyclylene-alkylene-R₂₂;

lll) —

U-alkylene-arylene-alkyl-R₂₂;

mmm) —

U-alkylene-heteroarylene-alkyl-R₂₂;

ppp) -hydrogen;

 

wherein

L₇ is a direct bond, -alkylene, -alkenylene, or -alkynylene;

U is a direct bond, —

CH₂—

, —

O—

, —

N(R₂₃)—

, —

C(O)—

, —

CON(R₂₃)—

, —

N(R₂₃)C(O)—

, —

N(R₂₃)CON(R₂₄)—

, —

N(R₂₃)C(O)O—

, —

OC(O)N(R₂₃)—

, —

N(R₂₃)SO₂—

, —

SO₂N(R₂₃)—

, —

C(O)—

O—

, —

O—

C(O)—

, —

S—

, —

S(O)—

, —

S(O₂)—

, —

N(R₂₃)SO₂N(R₂₄)—

, —

N═

N—

, or —

N(R₂₃)—

N(R₂₄)—

;

 

wherein

R₂₃ and R₂₄ are independently selected from the group consisting of;

-hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

X is

Y is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R₂₂ is —

SO₃H, —

P(O)(OH)₂, —

P(O)(O-alkyl)(OH), —

CO₂H, —

CO₂-alkyl, an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

17. The compound according to claim 1, wherein T is an aryl group subsituted by —

U-alkylene-R₂₂, wherein U is —

O—

or a direct bond, and R₂₂ is —

CO₂H or an acid isostere.

18. The compound according to claim 1, wherein

a and b are equal to zero;

L₁ is

Ar₂ is a phenylene group optionally substituted 1 time with a group consisting of;

—

Q-alkyl, wherein Q is —

O—

;

L₂ is a direct bond, O-alkylene, or an -alkynylene; and

T is an aryl group substituted with at least one substituent selected from the group consisting of;

a) —

U—

R₂₂;

b) —

U-alkylene-arylene-R₂₂;

c) —

U-alkylene-R₂₂;

d) —

U-arylene-R₂₂;

e) —

U-arylene-R₂₂ wherein the arylene is substituted with at least one of a halogen, methanesulfonylamino, or trifluoromethanesulfonylamino group.

f) —

U-arylene wherein the arylene is substituted with at least one trifluromethanesulfonylamino group;

g) —

R₂₂

h) -halogen

wherein R₂₂ is —

CO₂H or an acid isotere.

19. The compound according to claim 1, wherein

a and b are equal to zero;

R₁ is hydrogen;

W is —

N(R₂)—

, wherein R₂ is alkyl; and

Ar₁ is aryl substituted 2 times wherein the substituent groups are -chloro.

20. The compound according to claim 1, wherein W is —

N(R₂)—

, wherein R₂ is —

L₃—

D-alkylene-arylene-G, wherein L₃ is a direct bond or alkylene, D is a direct bond, or —

O—

, and G is —

CN, —

SO₃H, —

P(O)(OH)₂, —

P(O)(O-alkyl)(OH), —

CO₂H, —

CO₂-alkyl, or an acid isostere.

21. The compound according to claim 1, wherein a and b are equal to 0, and T, L₂, Ar₂, and L₁ together form a group selected from a group consisting of:

(E)-2-(4-methoxyphenyl)vinyl, (E)-2-(3-methoxyphenyl)vinyl, (E)-2-(2-methoxyphenyl)vinyl, (E)-2-(3,4-dimethoxyphenyl)vinyl, (E)-2-(2,3,4-trimethoxyphenyl)vinyl, (E)-2-(4-ethoxyphenyl)vinyl, (E)-2-phenylvinyl, (E)-2-(4-fluorophenyl)vinyl, (E)-2-(4-chlorophenyl)vinyl, (E)-2-(4-bromophenyl)vinyl, (E)-2-(1,1′

-biphenyl-4-yl)vinyl, (E)-2-(1-naphthyl)vinyl, (E)-2-(2-naphthyl)vinyl, 9H-fluoren-9-ylidenemethyl, (E)-2-(4′

-methoxy-1,1′

-biphenyl-4-yl)vinyl, (E)-2-(3′

-methoxy-1,1′

-biphenyl-4-yl)vinyl, (E)-2-(4-hydroxyphenyl)vinyl, 2-(4-methoxyphenyl)ethyl, (E)-2-(4′

-carboxymethyloxy-1,1′

-biphenyl-4-yl)vinyl, (E)-2-(4′

-(3-methoxycarbonyl-1-propyloxy)-1,1′

-biphenyl-4-yl)vinyl, (E)-2-(4′

-(3-carboxy-1-proploxy)-1,1′

-biphenyl-4-yl)vinyl, (E)-2-(4′

-phenoxy-1,1′

-biphenyl-4-yl)vinyl, and (E)-2-(4′

-benzyloxy-1,1′

-biphenyl-4-yl)vinyl.

22. The compound according to claim 1, wherein Ar₁ is:

2,4-dichlorophenyl.

23. The compound according to claim 1, where the compound of Formula (I) is:

4-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-3-fluoro-biphenyl-4-yloxymethyl)-benzoic acid;

4-(4-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-phenoxymethyl)-benzoic acid;

4-[4′

-(2-{4-(2,4-dichloro-phenyl)-1-[(1-naphthalen-1-yl-ethylcarbamoyl)-methyl]1H-imidazol-2-yl}-(E)-vinyl)-biphenyl-4-yloxy]-butyric acid;

4-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-butyric acid;

5-[3-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-propyl]-1H-tetrazole;

[4-(3-{2-[4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]-(E)-vinyl}-4-methoxy-phenyl-ethynyl)-phenoxy]-acetic acid;

4-[3-(4-{2-[4-(2,4-dichloro-phenyl)-1H-imidazol-2-yl]-(E)-vinyl}-phenylethynyl)-phenoxy]-butyric acid;

5-[3-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-propyl]-1H-tetrazole;

5-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-pentanoic acid

2-bromo-4-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-benzoic acid;

4-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxymethyl)-benzoic acid;

4-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-benzoic acid;

2-bromo-4-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-benzoic acid;

4-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-3-methanesulfonylamino-benzoic acid;

4-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-3-trifluoromethanesulfonyl-amino-benzoic acid;

5-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-2-methanesulfonylamino-benzoic acid;

5-(4′

-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-2-trifluoromethane-sulfonylamino-benzoic acid;

or

4-(4′

-{2-[4-(2,4-Dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-butyric acid 2,2-dimethyl-propionyloxymethyl ester.

24. A pharmaceutically acceptable salt, solvate, or prodrug of a compound of Formula (I) according to claim 1.

25. The pharmaceutical composition of claim 24, wherein said compound is applied to the skin.

26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1 sufficient to inhibit protein tyrosine phosphatase.

27. The pharmaceutical composition of claim 26, in the form of an oral dosage or parenteral dosage unit.

28. The pharmaceutical composition of claim 26, wherein said compound is administered as a dose in a range from about 0.003 to 500 mg/kg of body weight per day.

29. The pharmaceutical composition of claim 26, wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

30. The pharmaceutical composition of claim 26, wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

31. The pharmaceutical composition of claim 26, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, acarbose, PPAR agonists, DPP-IV inhibitors, GK activators, insulin, insulin mimetics, insulin secretagogues, insulin sensitizers, GLP-1, GLP-1 mimetics, cholinesterase inhibitors, antipsychotics, antidepressants, anticonvulsants, HMG CoA reductase inhibitors, cholestyramine, and fibrates.

32. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type I diabetes.

33. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type II diabetes.

34. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat immune dysfunction.

35. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat AIDS.

36. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat autoimmune diseases.

37. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat glucose intolerance.

38. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat obesity.

39. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat cancer.

40. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat psoriasis.

41. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat allergic diseases.

42. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat infectious diseases.

43. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat inflammatory diseases.

44. A phrmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat diseases involving the modulated synthesis of growth hormone.

45. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat diseases involving the modulated synthesis of growth factors or cytokines which affect the production of growth hormone.

46. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat Alzheimer'"'"'s disease.

47. A method of inhibition protein tyrosine phosphatases which comprises administering to a subject in need thereof a pharmacologically effective amount of a compound as claimed in claim 1.

48. A method of prevention and/or treatment of PTPase mediated human diseases, treatment comprising alleviation of one or more symptoms resulting from that disorder, to an outright cure for that particular disorder or prevention of the onset of the disorder, the method comprising administration to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1.

49. The method of claim 47, further comprising administering to a subject in need thereof at least one adjuvant and/or additional therapeutic agent(s).

50. A method of treating PTPase mediated diseases, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, in combination with one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, acarbose, PPAR agonists, DPP-IV inhibitors, GK activators, insulin, insulin mimetics, insulin secretagogues, insulin sensitizers, GLP-1, GLP-1 mimetics, cholinesterase inhibitors, antipsychotics, antidepressants, anticonvulsants, HMG CoA reductase inhibitors, cholestyramine, and fibrates.

51. A method for treating acute and/or chronic inflammation, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

52. A method for treating type I or type 11 diabetes, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

53. A method for treating immune dysfunction, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

54. A method for treating AIDS, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

55. A method for treating autoimmune disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

56. A method for treating glucose intolerance, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

57. A method for treating cancer, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

58. A method for treating psoriasis, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

59. A method for treating allergic diseases, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

60. A method for treating infectious disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

61. A method for treating diseases involving the modulated synthesis of growth hormone, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

62. A method for treating modulated synthesis of growth factors or cytokines which affect the production of growth hormone, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.

63. A method for treating Alzheimer'"'"'s disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.